Oracle

Articles

Is Oversight a Burden or Pivotal to Operational Efficiency?

May 24, 2022

Tuesday, May 24th, 2022 at 1pm EDT|10 am PDT|6pm BST|7pm CEST Simply handing off multi-million-dollar studies to CROs without carefully crafted plans for communications and reporting operational data as the study unfolds is hardly a wise move, yet what kind of oversight is needed? Technologies that track how studies unfold are essential but putting that information to good use requires turning real-time visibility into actionable data.

Accelerate critical insights from all digital, hybrid, and decentralized clinical trial data

May 12, 2022

Thursday, May 12, 2022 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST Many organizations have yet to figure out how to fit digital, hybrid, and decentralized clinical trial methods into their existing ecosystems in a scalable and efficient way. This webinar will go through the complexities that decentralized and hybrid methodologies bring to first-generation platforms, and how a single, unified platform enables interoperability and flexibility to help truly unlock the potential of these digital study methods.

The Next Domino: Automation, AI, and touchless safety case processing

February 15, 2022

With the increasing volumes of adverse event reports and stagnant budgets, the time is now for a revolutionary change in drug and device safety case management. A robust management process is necessary for identifying and evaluating adverse events (AE) and reporting them properly to regulators.

Smarter Signal Management: AI, big data, and predictive analytics

February 15, 2022

What if you could predict potential safety issues before clinical development begins? Innovative new signal detection and management approaches have been developed to help clinical trial sponsors, manufacturers, and CROs combat safety-related challenges and provide insight to be used to predict potential safety issues even before clinical development begins. Applying those learnings to their choice of initial research candidates can ultimately mean safer medicines for patients.